Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: Results from the Dresden NOAC Registry

Hecker, Judith, Marten, Sandra, Keller, Loretta, Helmert, Sindy, Michalski, Franziska, Werth, Sebastian, Sahin, Kurtulus, Tittl, Luise, Beyer-Westendorf, Jan · 2016 · Thrombosis and Haemostasis

Abstract

Summary: The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) demonstrated in ROCKET AF needs to be confirmed in daily care. To evaluate effectiveness and safety of rivaroxaban therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2700 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 1204 SPAF patients receiving rivaroxaban were enrolled. During a mean follow-up of 796.2 ± 207.3 days, the combined endpoint of stroke/transient ischaemic attack/systemic embolism occurred at a rate of 2.03/100 patient-years in the intention-totreat analysis (95 % confidence interval [CI] 1.5–2.7) and at 1.7/100 patient-years in the on-treatment analysis (events within 3 days after last intake). On-treatment rates were higher in patients selected for 15 mg rivaroxaban (n=384) once daily [OD] compared with the 820 patients selected for 20 mg OD (2.7 [95 % CI 1.6–4.2] vs 1.25/100 patient-years [95 % CI 0.8–1.9]). On treatment, major bleeding occurred at a rate of 3.0/100 patient-years and significantly more often in patients receiving the 15 mg OD dose compared with the 20 mg OD dose (4.5 vs 2.4/100 patient-years). Rivaroxaban treatment discontinuation occurred in a total of 277 patients during follow-up (12.0/100 patientyears in Kaplan-Meier analysis). Our data contribute to the confirmation of effectiveness and relative safety of rivaroxaban in daily-care patients. Furthermore, rivaroxaban discontinuation rates were considerably lower than those reported for vitamin K antagonists. Supplementary Material to this article is available online at www.thrombosis-online.com.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1160/th15-10-0840

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 159

Metadata

Authors
Hecker, J., Marten, S., Keller, L., Helmert, S., Michalski, F., Werth, S., Sahin, K., Tittl, L., & Beyer-Westendorf, J.
Venue
Thrombosis and Haemostasis
Published
2016
Volume
115
Issue
05
Pages
939-949
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W2314717641
Cited by
159
References
5
FWCI
27.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: Results from the Dresden NOAC Registry. https://app.cochat.ai/papers/10.1160/th15-10-0840
The paper
Hecker, J., Marten, S., Keller, L., Helmert, S., Michalski, F., Werth, S., Sahin, K., Tittl, L., & Beyer-Westendorf, J. (2016). Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis and Haemostasis. https://doi.org/10.1160/th15-10-0840

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.